Cover Image
Market Research Report

Anti-Infective Drugs Market: By Drug Type ; By Infection Type; and By Geography -Forecast 2019-2024

Published by IndustryARC Product code 421775
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Anti-Infective Drugs Market: By Drug Type ; By Infection Type; and By Geography -Forecast 2019-2024
Published: December 25, 2018 Content info:
Description

Anti-infective drugs can be defined as drugs which are capable of killing an infectious agent or inhibit it from spreading and are used for the purpose of killing and/or suppressing the infection causing organisms from invading the host organism by means of its replication or releasing variety of toxins in the host. Such infection causing micro-organisms include viruses, bacteria, fungi, viroids and macro parasites. This report is focused on identifying market size for anti-infective drugs globally. Increasing patient pool globally is one of the major drivers for the growth of the anti-infective drugs coupled with increasing R activities and increasing approval for new drugs.

This report identifies the anti-infective drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anti-infective drugs market.

Globally North America dominated market for anti-infective drugs in 2015 due to higher awareness about migraine and its effects and is estimated to continue the same during the period of study. North America was followed by Europe and Asia-Pacific as the second and third largest markets respective in 2015. Demand for anti-infective drugs in the Asia-Pacific region is estimated to be grow fastest during the period of study and is expected to be driven by large population pool, government initiatives of undertaking various control programs and private partnership projects and rising cost containment initiatives by drug manufacturers. This report on global anti-infective drugs also covers different classes of anti-infective drugs available and market size in various geographical regions.

On the basis of anti-infective drug type this report classifies as follows covering all major types of drugs available in the market: Antifungals (Allylamines, Azoles, Polyene Macrolides and Other Antifungals Diuretics), Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines and Others Calcium channel blockers), Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors and Other Antivirals Angiotensin-converting enzyme (ACE) inhibitors)

This report on global anti-infective drugs is also classified on the basis of infection type covering all major types of infections as follows: HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis and Other Infections

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anti-infective drugs in each of the region.

Sample Companies Profiled in this Report are:

Abbott Laboratories

Alcon Pharmaceuticals Ltd.

Astellas Pharma Inc.

AstraZeneca Plc

Bayer HealthCare AG

10+

Table of Contents

Table of Contents

1. Anti-Infective Drugs - Market Overview

2. Executive Summary

3. Anti-Infective Drugs Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. Anti-Infective Drugs - Market Forces

  • 4.1. Drivers
    • 4.1.1. Increasing number of patients pool globally
    • 4.1.2. Increasing drug approval
  • 4.2. Restraints
    • 4.2.1. Possible side effects over a long term
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Anti-Infective Drugs - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Global Anti-Infective Drugs Market, By Drugs Type (2014-2021)

  • 6.1. Antifungals
    • 6.1.1. Allylamines
    • 6.1.2. Azoles
    • 6.1.3. Polyene Macrolides
    • 6.1.4. Other Antifungals Diuretics
  • 6.2. Antibacterials
    • 6.2.1. Aminoglycosides
    • 6.2.2. Carbapenems
    • 6.2.3. Cephalosporins
    • 6.2.4. Macrolides
    • 6.2.5. Penicillins
    • 6.2.6. Quinolones
    • 6.2.7. Sulfonamides
    • 6.2.8. Tetracyclines
    • 6.2.9. Others Calcium channel blockers
  • 6.3. Antivirals
    • 6.3.1. Nucleoside Analogs
    • 6.3.2. Transcriptase Inhibitors
    • 6.3.3. DNA Polymerase Inhibitors
    • 6.3.4. Protease Inhibitors
    • 6.3.5. Other Antivirals Angiotensin-converting enzyme (ACE) inhibitors

7. Global Anti-Infective Drugs Market, By Infection (2014-2021)

  • 7.1. HIV
  • 7.2. Hepatitis B
  • 7.3. Hepatitis C
  • 7.4. Urinary Tract
  • 7.5. Respiratory Candidiasis
  • 7.6. Other Infections

8. Global Anti-Infective Drugs Market, By Geography (2014-2021)

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Anti-Infective Drugs - Market Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Top 10 Companies)

  • 10.1. Abbott Laboratories
    • 10.1.1. Introduction
    • 10.1.2. Financials
    • 10.1.3. Key Insights
    • 10.1.4. Key Strategy
    • 10.1.5. Product Portfolio
    • 10.1.6. SWOT Analysis
  • 10.2. Alcon Pharmaceuticals Ltd.
    • 10.2.1. Introduction
    • 10.2.2. Financials
    • 10.2.3. Key Insights
    • 10.2.4. Key Strategy
    • 10.2.5. Product Portfolio
    • 10.2.6. SWOT Analysis
  • 10.3. Astellas Pharma Inc.
    • 10.3.1. Introduction
    • 10.3.2. Financials
    • 10.3.3. Key Insights
    • 10.3.4. Key Strategy
    • 10.3.5. Product Portfolio
    • 10.3.6. SWOT Analysis
  • 10.4. AstraZeneca Plc
    • 10.4.1. Introduction
    • 10.4.2. Financials
    • 10.4.3. Key Insights
    • 10.4.4. Key Strategy
    • 10.4.5. Product Portfolio
    • 10.4.6. SWOT Analysis
  • 10.5. Bayer HealthCare AG
    • 10.5.1. Introduction
    • 10.5.2. Financials
    • 10.5.3. Key Insights
    • 10.5.4. Key Strategy
    • 10.5.5. Product Portfolio
    • 10.5.6. SWOT Analysis
  • 10.6. Bristol-Myers Squibb Co.
    • 10.6.1. Introduction
    • 10.6.2. Financials
    • 10.6.3. Key Insights
    • 10.6.4. Key Strategy
    • 10.6.5. Product Portfolio
    • 10.6.6. SWOT Analysis
  • 10.7. Boehringer Ingelheim
    • 10.7.1. Introduction
    • 10.7.2. Financials
    • 10.7.3. Key Insights
    • 10.7.4. Key Strategy
    • 10.7.5. Product Portfolio
    • 10.7.6. SWOT Analysis
  • 10.8. Sanofi-Aventis SA
    • 10.8.1. Introduction
    • 10.8.2. Financials
    • 10.8.3. Key Insights
    • 10.8.4. Key Strategy
    • 10.8.5. Product Portfolio
    • 10.8.6. SWOT Analysis
  • 10.9. Novartis AG
    • 10.9.1. Introduction
    • 10.9.2. Financials
    • 10.9.3. Key Insights
    • 10.9.4. Key Strategy
    • 10.9.5. Product Portfolio
    • 10.9.6. SWOT Analysis
  • 10.10. GlaxoSmithKline Plc
    • 10.10.1. Introduction
    • 10.10.2. Financials
    • 10.10.3. Key Insights
    • 10.10.4. Key Strategy
    • 10.10.5. Product Portfolio
    • 10.10.6. SWOT Analysis

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Expert Insights
Back to Top